Journal Information
Vol. 13. Issue 6.
Pages 869-877 (November - December 2007)
Share
Share
Download PDF
More article options
Vol. 13. Issue 6.
Pages 869-877 (November - December 2007)
Caso Clínico / Clinical Case
Open Access
A tuberculose multirresistente e a rainha vermelha – A rapidez do diagnóstico é decisiva
Multi-drug resistant tuberculosis and the red queen – Diagnosis speed is crucial
Visits
6138
João Costeira1, Jaime Pina2
1 Assistente Hospitalar Graduado de Pneumologia, Hospital de Pulido Valente, EPE, Alameda das Linhas de Torres, 117 1769-001 Lisboa
2 Chefe de Serviço Hospitalar de Pneumologia e Director do Serviço de Pneumologia 2 do Hospital de Pulido Valente, Lisboa
Related content
João Costeira, Jaime Pina
This item has received

Under a Creative Commons license
Article information
Resumo

A tuberculose multirresistente é uma ameaça importante ao controlo da tuberculose.

Neste sentido, é fundamental o diagnóstico precoce da TBMR para adoptar as medidas mais adequadas. Os métodos de detecção da resistência aos antibacilares baseados na avaliação das determinantes genéticas (métodos genotípicos) têm a vantagem, em relação aos métodos clássicos (fenotípicos), de serem mais céleres, poderem ser aplicados directamente na amostra clínica e de identificarem simultaneamente o Myco-bacterium tuberculosis complex.

A análise dos dados dos doentes internados no Serviço de Pneumologia 2 do Hospital de Pulido Valente mostrou uma significativa prevalência de TBMR (10,3%). Revelou, também, que em 34,1% dos doentes com TBMR a multirresistência não foi identificada, tendo sido a mortalidade nesses doentes de 31% versus 18,4% nos doentes com o perfil de resistências previamente conhecido. Estes valores são piores nos doentes com TBMR+SIDA, que têm uma mortalidade de 50% versus 15%, respectivamente.

Para uma rápida identificação das resistências nos doentes internados no Serviço de Pneumologia 2 do HPV, foi avaliado o teste INNO-LIPA Rif.TB para detecção da resistência à RMP como marcador de multirresistência. Os resultados do teste, efectuado em 113 amostras, mostraram elevadas taxas de sensibilidade (91,6%), especificidade (98%), valor preditivo positivo (84,6%) e valor preditivo negativo (99%).

A demora média para obter os resultados foi de 7,6 dias para o teste genotípico versus 23,4 dias para o teste fenotípico (BACTEC MGIT 960).

Actualmente, o teste INNO-LIPA Rif. TB é aplicado em todos os doentes internados com tuberculose bacilífera sem perfil de resistências previamente conhecido, com bons resultados.

Rev Port Pneumol 2007; XIII (6): 869-877

Palavras-chave:
Tuberculose multirresistente
método genotípico
sensibilidade
especificidade
Abstract

The multi-drug resistant Tuberculosis (MDRTB) is a huge menace to Tuberculosis control.

The early detection of MDRTB is essential to best appropriate measures.

The detection methods for drug resistance based in evaluation of the genetic determinants (genotypic methods), instead of phenotypic methods, allows for faster results, the possibility of direct application in clinical samples and simultaneous identification of Mycobacterium tuberculosis complex.

The inpatients data analysis in the “Serviço de Pneumologia 2 do Hospital Pulido Valente”, showed a high prevalence of MDRTB (10.3%). In 34.1% of the MDRTB patients the multi-drug resistance was not been identified, with a mortality ratio in this cases of 31% versus 18.4% in the subset of patients with resistance previously identified. Moreover the mortality ratio was worst in MDRTB/AIDS patients with 50% versus 15%, respectively.

Targeting for rapid drug resistance detection, in hospitalized patients at “Serviço de Pneumologia 2 do Hospital Pulido Valente”, the test INNO-LIPA Rif.TB, to identify the rifampicin resistance as a marker of multi-drug resistance, was evaluated.

The test was performed in 113 samples and had a high ratio of sensitivity (91.6%), specificity (98%), positive predictive value (84, 6%) and negative predictive value (99%).

Time to obtain the results was 7.6days for the genotypic test versus 23.4days to the phenotypic test (BACTEC MGIT 960).

The INNO-LIPA Rif.TB test is, now, performed in every patient with smear-positive Tuberculosis with no previous knows resistance profile, with good outcome.

Rev Port Pneumol 2007; XIII (6): 869-877

Key-words:
Multi-drug resistant tuberculosis
genotypic method
sensitivity
specificity
Full text is only aviable in PDF
Bibliografia
[1.]
G.P. Youmans, E.H. Williston, W.H. Feldman, H.C. Hinshaw.
Increase in resistance of tubercle bacilli to streptomycin, preliminary report.
Mayo Cli, 21 (1946), pp. 126-127
[2.]
S. Sungkanuparh, B. Eampokalap, S. Chottanapund, S. Thongyen, W. Manosuthi.
Impact of drug-resistant tuberculosis on the survival of HIV-infected patients.
Int J Tuberc Dis, 11 (2007), pp. 325-330
[3.]
D.A. Mitchison.
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Int J Tuberc. Lung Dis, 2 (1998), pp. 10-15
[4.]
D.A. Mitchison, A.J. Nunn.
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Am Rev Respir Dis, 133 (1986), pp. 423-430
[5.]
WHO.
Treatment of Tuberculosis. Guidelines for national programmes, 3, World Health Organization, (2003),
[6.]
T.R. Frieden, T. Sterling, A. Pablos-Mendez, J.O. Kilburn, G.M. Cauthen, S.W. Dooley.
The emergence of drug-resistant tuberculosis in New York City.
N Engl J Med, 328 (1993), pp. 521-526
[7.]
Nosocomial transmission of multi-drug resistant tuberculosis among HIV-infected persons – Florida and New York, 1988-1991.
MMWRMorb Mortal Wkly Rep, 40 (1991), pp. 585-591
[8.]
H.T. Quy, F.G. Cobelens, N.T. Lan, T.N. Buu, C.S. Lambregts, M.W. Borgdorff.
Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam.
Int J Tuberc Lung Dis, 10 (2006), pp. 45-51
[9.]
C.Y. Chiang, D.A. Enarson, M.C. Yu, K.J. Bai, R.M. Huang, C.J. Hsu, J. Suo, T.P. Lin.
Outcome of pulmonary multidrug-resistant tuberculosis: a 6yr follow-up study.
Eur Respir J, 28 (2006), pp. 980-985
[10.]
S. Sungkanuparh, B. Eampokalap, S. Chottanapund, S. Thongyen, W. Manosuthi.
Impact of drug-resistant tuberculosis on the survival of HIV-infected patients.
Int J Tuberc Dis, 11 (2007), pp. 325-330
[11.]
World Health Organization.
Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control.
Wkly Epidemiol Rec, 81 (2006), pp. 430-432
[12.]
G.B. Migliori, J. Ortmann, E. Girardi, G. Besozzi, C. Lange, D.M. Cirillo, M. Ferrarese, G. Iaco, A. Gori, M.C. Raviglione, SMIRA/TBNET Study Group.
Extensively Drug-resistant Tuberculosis, Italy and Germany.
CDC Emerging Infectious Diseases, 13 (2007), pp. 780-782
[13.]
S.K. Sharma, A. Mohan, A. Multidrug-Resistant Tuberculosis.
Menace That Threatens To Destabilize Tuberculosis Control.
Chest, 130 (2006), pp. 261-272
[14.]
G.B. Migliori, R. Loddenkemper, F. Blasi, M.C. Raviglione.
125 years after Robert Koch’s discovery of the tubercule bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?.
Eur Respir J, 29 (2007), pp. 423-427
[15.]
N.R. Gandhi, A. Moll, A.W. Sturn, R. Pawinski, T. Govender, U. Lallo, K. Zeller, J. Andrews, G. Friendland.
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
Lancet, 368 (2006), pp. 1575-1580
[16.]
P. Nahid, M. Pai, P. Hopewell.
Advances in the Diagnosis and Treatment of Tuberculosis.
Proc Am Thorax Soc, 3 (2006), pp. 103-110
[17.]
E. Tortoli, J.C. Palomino.
Chapter 14 New Diagnostic Methods, pp. 441-486
[18.]
Anandi Martin, Françoise Portaels.
Chapter 19: Drug Resistance and Drug Resistance Detection, Tuberculosis, pp. 635-660
[19.]
H. Traore, A. Deun, I.C. Shamputa, L. Rigouts, F. Portaels.
Direct Detection of Mycobacterium tuberculosis Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe Assay.
Journal of Clinical Microbiology, 44 (2006), pp. 4384-4388
[20.]
M. Viveiros, C. Leandro, L. Rodrigues, J. Almeida, R. Bettencourt, I. Couto, et al.
Direct Application of the INNO-LIPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multidrug-Resistant Tuberculosis.
Journal of Clinical Microbiology, 43 (2005), pp. 4880-4884
[21.]
M. Morgan, S. Kalantri, L. Flores, M. Pai.
A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
BMC infectious Diseases, 5 (2005), pp. 62
[22.]
M. Viveiros, C. Leandro, L. Rodrigues, J. Almeida, R. Bettencourt, I. Couto, et al.
Diagnóstico da Tuberculose O Programa “Faster-Track” de Combate à Tuberculose Multirresistente na Grande Lisboa, pp. 83-99
[23.]
S.H.E. Kaufmann, S.T. Cole, V. Mizrahi, E. Rubin, C. Nathan.
Mycobacterium tuberculosis and the host response.
J Exp Med, 6 (2005), pp. 1963-1967
[24.]
N.W. Schluger.
The Pathogenesis of Tuberculosis, The First One Hundred (and Twenty-Three) Years.
Am J Respir Cell Mol Biol, 32 (2005), pp. 251-256
[25.]
L. Van Valen.
A new evolutionary law.
Evolutionary Theory, 1 (1973), pp. 1-30
[26.]
L. Carrol.
Through the looking glass and what Alice found there, MacMillan, (1872),
Copyright © 2007. Sociedade Portuguesa de Pneumologia/SPP
Download PDF
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?